General information, not legal or regulatory advice. Confirm current ethics and national-file rules with qualified advisers. We do not invent clocks, rates, or named studies that are not on the locked public sources cited here. No patient data. No unpublished client. Always bioaccess®.
If you searched Avania Australia FIH medical device CRO, Avania Melbourne Sydney first-in-human implant, cSDH liquid embolic FIH Australia, you were looking for a first-in-human / early-feasibility medical-device CRO in Australia. Competitor watch on this cluster is the named AU/IL/CA FIH CRO set only: Avania, Novotech, GreenLight Clinical, Bioforum, JSS Medical Research. We do not invent extra CRO brands. We do not invent extra named sponsors. We do not sell insurance. We do not name a carrier as a signed partner. Nanochon stays HOLD. NextLife is not a new steal. Magical BTK stays off this page. No PHI.
Avania is a global MedTech CRO with Melbourne and Sydney offices. It is on this page because it is the shop actually publishing Australian hospital-implant FIH cases — not because we invented a boutique. Public Avania neurovascular copy describes a liquid-embolic cSDH first-in-human with Australia ethics and regulatory “within 3 months” (company claim) and multicenter expansion started. The sponsor on that page is unnamed. We will not infer it. The steal is the expansion, the next neurovascular FIH, or the next implant protocol that would otherwise stay in ANZ because Avania already ran the first cases.
This page is not a leftover-site hospital intercept and not an insurance intercept. Distinct slug. Distinct title. The job is country 2: keep Australia if it is already running, add Latin America for the next protocol, the expansion, or the backup geography. Eligibility of foreign data under 21 CFR 812.28 is not FDA clearance. See OUS FIH and FDA IDE.
What this search is actually buying
You are not buying an Australian tax incentive. You are buying ISO 14155 hospital implant ops, ethics, import, and an n that can travel toward an FDA IDE. Avania’s public pitch on the unnamed PDAC implantable paclitaxel-device FIH is KOLs plus tax incentives and an Australia-first start that later “advanced to global Phase II.” Current Phase I is locked. Steal is Phase II LATAM sites or the next implant-combo protocol. Do not invent that sponsor either — several paclitaxel-device programs exist; similarity is not proof.
What the locked Avania AU cases actually say
Locked source: the 28 Aug 2026 CRO case-study steal list, public Avania therapeutic-area pages. Rank 1 is the unnamed cSDH liquid-embolic FIH (Australia ethics/regulatory + enrollment stated). Rank 2 is the unnamed PDAC implantable FIH labelled FIH / Phase I, Australia initial study. Rank 3 is the only named-sponsor AU implant FIH in that month’s set: Alessa Therapeutics Biolen-PC (bicalutamide-eluting silicone implant), NCT04284761, AU+NZ, primary completion 3 May 2023 on ClinicalTrials.gov. That study is finished. It is historic next-protocol only. We will not flip Alessa into a live steal mail from this page. USANZ named Avania on that study; Alessa’s own enrollment release did not. Quote the public pages, not a hallway.
What we will not invent
We will not name the cSDH sponsor. We will not name the PDAC sponsor. We will not infer Capstan, Versa, or any other public TMVR onto Avania’s unnamed TMVR EFS (that case is Europe + United States on Avania’s cardiovascular page — not this Australia intercept). We will not add NextLife. We will not add Greenlight Guru. Avania’s late/post-market rows (flow-diverter PMA, Quanta 510(k), hydrogel embolic stats) are not FIH steals. Nanochon stays HOLD.
Country 2 is LATAM. It is not a second Australian CTN, and it is not a new Colombian FIH CTA
If Australia already enrolled the first n, country 2 is a Latin American satellite or the next protocol — Panama ethics typically 3–5 weeks and protocol-to-first-patient 6–8 weeks on the live Panama hub; Chile ISP on the order of 30 business days for study review; Brazil combined ethics + ANVISA typically 6–10 weeks under Law 14874 / RDC 837/2023; Mexico ethics 4–6 weeks and COFEPRIS 4–8 weeks after ethics on the live Mexico hub. No AU entity. No R&DTI wait. Do not book a second CTN just because Avania is already in Melbourne.
Use clinical-trials-panama. Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national file. Ethics review runs through institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). Published ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks on that hub. Per-patient costs there: $12,000–$22,000 in U.S. dollars. A hallway conversation at this hospital is not MINSA clearance.
Use clinical-trials-chile. Instituto de Salud Pública (ISP) authorizes studies and investigational-device import. Live Chile blogs already put a typical ISP review in a band of about 30 business days. Commercial ISP registration in a 30–90 day band is a different file — do not put trial authorization and commercial registro on one Gantt labeled “Chile.” An Ethical-Scientific Committee under Law 20.120 still has to sit. We will not invent PAHO/WHO Level 4 standing for ISP on this page.
Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.
Use clinical-trials-mexico and CRO in Mexico. Ethics typically 4–6 weeks and COFEPRIS review typically 4–8 weeks after ethics on the live Mexico hub; combined start-up is cited there as a 2.8-month median. Keep trial clocks separate from registro sanitario (~30 working days on that hub). Eligibility of foreign data under 21 CFR 812.28 is not a guarantee of clearance.
El Salvador is a public bioaccess® geography (DNM on llms.txt; live hub at clinical-trials-el-salvador). We will not invent a new Salvadoran clock here.
Colombia stays market access
Public line, unchanged: INVIMA commercial medical-device registration remains a core bioaccess® service. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. Country 2 on this cluster is Panama, Chile, Brazil, Mexico, or El Salvador — not a new Colombian FIH CTA. The Panama country page still publishes ethics 3–5 weeks vs. Colombia 4–6 weeks and per-patient $12K–$22K vs. $15K–$25K. Always bioaccess®. The founder podcast is Global Trial Accelerators™.
Historic Colombia FIH on public bioaccess® pages is not a reason to book a new INVIMA FIH from this cluster. Do not treat a Bogotá hospital NCT row as country 2.
What bioaccess® still owns on the steal
- ISO 14155 field-clinical, not a Phase I unit brochure. Hospital implant and interventional sites in Panama, Chile, Brazil, Mexico, El Salvador as the device needs.
- Protocol, IB, ICF, ethics / national file in the same stack. A hallway conversation at an Australian private hospital is not that file.
- Importer of record and device accountability. See importer of record for clinical trial devices in Latin America. A CTN or Health Canada CTA does not import the investigational product into Latin America.
- 21 CFR 812.28 narrative if the next stop is an FDA IDE. Eligibility of foreign data is not a guarantee of clearance.
- No AU / IL / CA legal entity required to start country 2. Do not wait on R&DTI, a second CTN, or a Toronto MSA to generate the next n.
The firm was founded in 2010. Public device case studies already on llms.txt (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as published) show FIH execution. We will not invent a new named client onto this page.
Frequently asked questions
Is bioaccess® trying to replace the incumbent CRO on a live protocol?
No. If Avania, Novotech, GreenLight Clinical, Bioforum, or JSS is already running country 1, the steal is the next protocol, the expansion, or a LATAM satellite — not a mid-study rip-out we invent.
Do you sell clinical trial insurance on this page?
No. We are the FIH CRO. Insurance intercepts live on their own slugs. We do not underwrite. We do not name HDI as a partner here.
Is Colombia the country-2 default?
No. New FIH execution is not the Colombia CTA on this cluster. INVIMA registro remains. See the Colombia paragraph above.
Next step
If the search that brought you here was Avania Australia as the FIH medical-device CRO, start as the operator: contact bioaccess® or book from First-in-Human CRO. Sibling (do not clone): Avania Canada. Country-2 NCT intercept: Australia-only NCT → LATAM.
Julio G. Martinez-Clark, CEO · bioaccess®